The Van Gogh-extension Trial, a Multicenter, International, Randomized, Double-blind, Study Comparing the Efficacy and Safety of Once-weekly Subcutaneous SR34006 With Placebo in the Long-term Prevention of Symptomatic Venous Thromboembolism in Patients With Symptomatic Pulmonary Embolism or Deep-vein Thrombosis Who Completed 6 Months of Treatment With Vitamin K Antagonist or SR34006

Inclusion Criteria:

- Patients with confirmed symptomatic Pulmonary Embolism (PE) or Deep Vein Thrombosis
(DVT) who have been treated with acenocoumarol, warfarin or SR34006 for six months

- Written informed consent

Exclusion Criteria:

- Legal age limitations (country specific)

- Indication for anticoagulation other than PE or DVT

- Creatinine clearance (CLcr) <10 mL/min, severe hepatic disease, or bacterial
endocarditis

- Participation in a pharmacotherapeutic study other than the Van Gogh-PE or DVT study
within the prior 30 days

- Life expectancy <3 months

- Patients in whom anticoagulation treatment for their index PE or DVT should be
continued beyond 6 months

- Active bleeding or high risk for bleeding

- Uncontrolled hypertension: systolic blood pressure >180 mm Hg or diastolic blood
pressure > 110 mm Hg

- Pregnancy, or childbearing potential without proper contraceptive measures, women who
are breastfeeding.